Merck Reports Encouraging Results from Trial

Merck & Company shares were up over 2% pre-market Tuesday after the drug maker reported positive results from the second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of doravirine, the company’s investigational treatment for HIV-1 infection.

At 48 weeks, the study showed that a once-daily single tablet, fixed-dose combination of doravirine (DOR), lamivudine (3TC), and tenofovir disoproxil fumarate (TDF) met its primary efficacy endpoint. Data “show that a fixed-dose combination tablet containing doravirine achieved viral suppression in HIV-1 infected treatment-na├»ve adults, comparable to a fixed-dose combination containing efavirenz,” said Kathleen Squires, one of the study’s investigators. “The results for doravirine are encouraging, as it may offer appropriate patients a new single-tablet treatment option.”

Leave a Comment